amount to a decrease rate of 13.14 percent in 2019. The Company’s gross profit margins in 2018 – 2019 were equal to 17.14 percent and 19.89 percent, respectively. The increase in the gross profit market
period ended June 30, 2020, resulted in increase in total comprehensive income of Baht 59.64 million or 283.00% from the corresponding period of the previous year as the following details below: 1. Revenue
of following key factors: 1. Revenue from sales of electricity were THB 173 million in the third quarter of 2020, which increased by THB 81 million or 89% from the same period last year. The increase
17.74% 20.03 9.21% 49.42 246.73% Jul – Sep 63 Jul – Sep 62 Increase/(Decrease) DOD BIOTECH PUBLIC COMPANY LIMITED เลขที่ 111 หมู่ที่ 2 ตาํบลท่าจนี อาํเภอเมืองสมุทรสาคร จงัหวดัสมุทรสาคร 74000 111 Moo 2
more than its target, which reflected in 2019 gross margin increase by 250 bps YoY to 34.9%. Q4’19 Gross margin was slightly improved 50 bps YoY and recorded at 35.0%, despite the impact of new sugar tax
Company, wishes to raise funds through an increase of its registered capital and offer such newly issued ordinary shares to the public by an initial public offering (the “IPO”) and subsequently list its
early 2018. - OSP energy drink market share was at 54%. Q4’18 M150 market share was at 37.9% increase by 90bps QOQ. C-Vitt took over leadership position in functional drink market, with Q4’18 market share
. 2Q 2019 PERFORMANCE ANALYSIS (YoY) In 2Q 2019, the Company reported a consolidated operating revenue of THB 690mn, a significant increase of 161.5% YoY from THB 264mn in 2Q 2018. The revenue comprised
additional provision of THB 20 Million due to increase in the benefit of employees who have past service of 20 years or more from 300 days to 400 days according to the announcement of Labour Protection Act
7,930.03 8,296.77 Increase (Decrease) % Quarter 2 The operating result according to the consolidated financial statement for the 2 nd quarter of 2019 showed the profit (attributable to owners of the Company